{"id":125034,"date":"2024-01-04T13:15:14","date_gmt":"2024-01-04T13:15:14","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=115488"},"modified":"2024-01-04T13:15:14","modified_gmt":"2024-01-04T13:15:14","slug":"recursion-adds-new-chemical-entity-targeting-fibrotic-diseases-to-late-discovery-pipeline","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/recursion-adds-new-chemical-entity-targeting-fibrotic-diseases-to-late-discovery-pipeline\/","title":{"rendered":"Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline"},"content":{"rendered":"
SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion<\/a> (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies\u2019 fibrosis research collaboration. The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction.<\/p>\n \u201cSince initiating our research collaboration with Bayer in 2020, we have worked diligently to apply the power of the Recursion OS to identify and advance potential candidates in challenging areas of disease biology,\u201d said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. \u201cWe are excited to bring this asset into our internal pipeline and accelerate the compelling science behind this program while our research collaboration with Bayer focuses on precision oncology.\u201d<\/p>\n Recursion applied phenotypic screening of human cells to identify small molecules that reverse the phenotypic features of disease-state fibrocyte cells into those of healthy-state cells. Leveraging the power of Recursion\u2019s Maps of Biology and Chemistry revealed a relationship between small molecule hits and a novel target that could impact fibrotic diseases. The most promising small molecule hits were confirmed as potent inhibitors of this novel target in validation experiments, and lead optimization studies are currently ongoing.<\/p>\n Fibrotic diseases are a significant cause of morbidity and mortality worldwide with high unmet need for patients. One of the biggest challenges in the treatment of fibrotic diseases is the underlying complex biology and the associated difficulty in discovering disease-modifying drug targets. Recursion\u2019s technology is uniquely suited to accelerate discoveries in these and other complex areas of disease biology.<\/p>\n About Recursion<\/strong> Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive<\/u><\/a>, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montr\u00e9al and the San Francisco Bay Area. Learn more at www.Recursion.com<\/u><\/a>, or connect on Twitter<\/u><\/a> and LinkedIn<\/u><\/a>.<\/p>\n Media Contact<\/strong>
\nRecursion<\/u><\/a> (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world\u2019s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale \u2014 up to millions of wet lab experiments weekly \u2014 and massive computational scale \u2014 owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.<\/p>\n
\nMedia@Recursion.com<\/a><\/p>\n